Editas Medicine, Inc. (EDIT) Stock Profile — Insider Trades & Financials

Revenue$24.7M

Net Income-$5.6M

EPS$-1.80

Market Cap$268.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

James Mullen

CEO & Executive Director

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Founded: 2013
Employees: 226
Headquarters: CAMBRIDGE, MA, United States
Website: www.editasmedicine.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

-20.60%

ROA?

-3.01%

D/E Ratio?

5.84

Op. Margin?

-31.34%

📊

Profitability Ratios

Net Margin?

-22.72%

Loading company sections...

Editas Medicine, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness